Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Kidney Health in a Changing Climate: Emerging Disease Patterns and Driving Mechanisms.

Kidney360·2026

Same author

EPI-CKD Brazil: point-of-care screening for chronic kidney disease during World Kidney Day.

Jornal brasileiro de nefrologia·2026

Same author

Patients with chronic kidney disease stage 3b: do general practitioners and nephrologists follow KDIGO guidelines?

Jornal brasileiro de nefrologia·2026

Same author

Th17 cells require the DNA repair sensor xeroderma pigmentosum complementation Group C to control oxidative DNA damage in a murine model.

Nature communications·2026

Same author

Extracellular Vesicles Facilitate the Crosstalk Between High Glucose-Stimulated Mesangial Cells and Healthy Podocytes to Mediate Injury Responses.

International journal of molecular sciences·2026

Same author

JAK3 Staining and CD68+ Macrophage Counts Are Increased in Patients with IgA Nephropathy.

Diagnostics (Basel, Switzerland)·2026

Search research articles

Related Experiment Video

Updated: Oct 26, 2025

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

Renal lipotoxicity: Insights from experimental models.

Barbara Bruna Abreu Castro^1,2, Orestes Foresto-Neto³, Niels Olsen Saraiva-Camara³

¹Laboratory of Experimental Nephrology, Nucleus of Animal Experimentation (NIDEAL), Centre of Reproductive Biology (CBR), Federal University of Juiz de Fora (UFJF, Juiz de Fora, Minas Gerais, Brazil.

Clinical and Experimental Pharmacology & Physiology

|July 27, 2021

Summary

Obesity increases kidney disease risk by causing renal lipotoxicity. Excess lipids harm kidney cells, leading to dysfunction and fibrosis, highlighting the need for therapeutic targets.

Keywords:

fatty acids high-fat diet hyperlipidaemia kidney diseases lipid metabolism disorders

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Related Experiment Videos

Last Updated: Oct 26, 2025

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Area of Science:

Nephrology
Metabolic Disorders
Cellular Biology

Background:

Rising global prevalence of obesity and chronic kidney disease.
Established link between obesity and renal lipotoxicity.
Lipid accumulation in kidney cells can impair function and cause fibrosis.

Purpose of the Study:

To review mechanisms of renal lipotoxicity in obesity.
To summarize how lipotoxicity affects kidney morphology and function.
To identify potential therapeutic targets for obesity-related kidney dysfunction.

Main Methods:

Review of experimental models of obesity.
Analysis of cellular and organelle dysfunction due to lipid accumulation.
Examination of pathways linking lipotoxicity to kidney injury.

Main Results:

Fatty acid accumulation in tubular cells is a key mechanism.
Lipids impact podocyte function and survival.
Mitochondrial, lysosomal, and endoplasmic reticulum alterations contribute to kidney damage.

Conclusions:

Kidneys are highly susceptible to lipotoxicity.
Understanding lipotoxicity mechanisms is crucial for managing obesity-related kidney disease.
Identifying therapeutic targets may help control renal dysfunction.